Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04529252 · ClinicalTrials.gov registry record

Investigating the Genetic and Phenotypic Presentation of Ataxia and Nucleotide Repeat Diseases

A clinical trial of Cerebellar Ataxia and Spinocerebellar Ataxias, sponsored by Mayo Clinic.

Recruiting
Registry status
1,000
Enrollment target
1
Study location

NCT04529252: Recruiting study of Cerebellar Ataxia and Spinocerebellar Ataxias, sponsored by Mayo Clinic.

NCT04529252 is a study of Cerebellar Ataxia and Spinocerebellar Ataxias that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 1,000 participants, above the 151-participant average among 5 other Cerebellar Ataxia trials with a reported enrollment target (562% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04529252, a study of Cerebellar Ataxia and Spinocerebellar Ataxias, is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
1,000 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to create a repository for cerebellar ataxia and nucleotide repeat diseases in order to fully investigate the genetic and phenotypic presentations of both.

Primary Outcome

Specimen sample collection to create a repository for genetic neurodegenerative forms of spinocerebellar ataxia and nucleotide repeat diseases not including Huntington's disease

Interventions

  • OTHER Specimen collection

Study Locations (1)

Florida

  • Mayo Clinic in Florida - Jacksonville

Trial Details

FieldValue
Enrollment Target 1,000 participants
Start Date 2017-07-17
Est. Completion 2026-12
Mayo Clinic

2,844 total trials

What NCT04529252 shows while recruiting

NCT04529252 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 151-participant average among 5 other Cerebellar Ataxia trials with a reported enrollment target (562% higher).

The record links to 3 conditions, with Cerebellar Ataxia appearing as the primary indexed condition, and to 1 intervention - of which Specimen collection is the first listed.

NCT04529252 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT04529252 about?

NCT04529252 is a clinical study titled "Investigating the Genetic and Phenotypic Presentation of Ataxia and Nucleotide Repeat Diseases". The purpose of this study is to create a repository for cerebellar ataxia and nucleotide repeat diseases in order to fully investigate the genetic and phenotypic presentations of both.

What is the current status of trial NCT04529252?

This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2017-07-17. Estimated completion is 2026-12.

What conditions does trial NCT04529252 study?

This clinical trial studies the following conditions: Cerebellar Ataxia, Spinocerebellar Ataxias, Nucleotide Repeat Disease.

What interventions are being tested in trial NCT04529252?

The interventions under investigation include: Specimen collection (OTHER).

Who is sponsoring clinical trial NCT04529252?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04529252 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cerebellar Ataxia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00018044 · 1,000 participants

    Study of Mycobacterial Infections

  • NCT01036581 · 1,000 participants · NA

    Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging

  • NCT01192048 · 1,000 participants

    Genetics of Congenital Heart Disease

  • NCT01553214 · 1,000 participants · Phase 4

    Improving White Blood Cell Collection From Healthy Donors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04529252, the US trial registry maintained by the National Library of Medicine. NCT04529252 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.